Mariner
CRDF icon

Mariner’s Cardiff Oncology CRDF Stock Holding History

Mariner’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.2K Buy
49,356
+34,905
+242% +$55.4K ﹤0.01% 3393
2026
Q1 		$23.4K Buy
+14,451
New +$29.7K ﹤0.01% 3483
2025
Q3 		– Sell
-18,149
Closed -$57.2K – 3602
2025
Q2 		$57.2K Sell
18,149
-164
-0.9% -$500 ﹤0.01% 3329
2025
Q1 		$57.5K Buy
18,313
+4,266
+30% +$16.9K ﹤0.01% 3293
2024
Q4 		$61K Buy
+14,047
New +$43.9K ﹤0.01% 3267

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Mariner's CRDF Position: Q2 2026 in Review

Mariner increased its Cardiff Oncology (CRDF) stake by 242% in Q2 2026, buying an estimated $55.4K and bringing the position to 49,356 shares worth $64.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3393.

Mariner first reported a position in CRDF in Q4 2024 and has held it in 5 quarters since. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Mariner held 49,356 shares of Cardiff Oncology worth $64.2K as of Q2 2026.
  • Mariner bought 34,905 Cardiff Oncology shares in Q2 2026, an estimated $55.4K.
  • Cardiff Oncology made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3393 holding.
  • Mariner first reported a position in Cardiff Oncology in Q4 2024 and has held it in 5 quarters since.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.